# OnCo record luminosity (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/luminosity/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "luminosity", "NCT03539536" ;
  schema:name "LUMINOSITY"@en ;
  schema:description "The single-arm study behind the first c-Met-directed antibody-drug conjugate approval in lung cancer: tumours shrank in about a third of patients whose cancers carried high c-Met protein, with eye and nerve side effects to watch."@en ;
  schema:url <https://onco.cc/trials/luminosity/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03539536>, <https://doi.org/10.1200/JCO.24.00720> ;
  onco:status "positive" ;
  onco:phase "2" ;
  schema:startDate "2018-10-10" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/met-altered-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/met/> ;
  onco:drugs <https://onco.cc/drugs/telisotuzumab-vedotin/> ;
  onco:companies <https://onco.cc/companies/abbvie/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-luminosity-j-clin-oncol-2024/>, <https://onco.cc/key-papers/paper-luminosity-jto-clin-res-rep-2026-update/> .